Seagen shares data for Adcetris combination for Hodgkin Lymphoma

pharmafile | December 13, 2022 | News story | Research and Development  

Adcetris has long been one of Seagen’s top-selling and expanding products, and it has announced that the drug appeared successful especially when used in combination with other therapies. Seagen has shared data from its recent phase 2 clinical trial evaluating Adcetris in combination with Bristol Myers Squibb’s PD-1 inhibitor Opdivo, as well as standard of care chemotherapy treatments.

The trial evaluated the drug in combination with other chemotherapies for the frontline treatment of patients with classical Hodgkin Lymphoma, as well as other parts of the trial which assessed patients with advanced- and early-stage disease. The results of the latter part of the trial are due to be announced at the American Society of Hematology’s annual meeting.

Seagen reported that there was a complete response rate of 88% as well as an overall response of 93% in patients in the advanced stage of the disease. Patients in the early stage of disease saw a complete response of 92% and an overall response rate of 95%.

Marjorie Green, head of late-stage development at Seagen, said in an earlier statement: “The investigation of Adcetris as a single agent or in novel combinations with other agents demonstrates its continued potential to help people impacted by early- and advanced-stag Hodgkin Lymphoma. Additional data from real-world settings further supports the efficacy, safety and impact of Adcetris treatment in its approved indications for multiple types of lymphoma.”


Betsy Goodfellow

Related Content

No items found

Latest content